Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: Case report and review of the literature of alopecia associated with EGFR inhibitors

Dermatology

Volumn 225, Issue 1, 2012, Pages 18-21

  Toda, Nagomi ^a   Fujimoto, Noriki ^a   Kato, Takeshi ^a   Fujii, Norikazu ^a   Nakanishi, Gen ^a   Nagao, Taishi ^a   Tanaka, Toshihiro ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Alopecia; Epidermal growth factor receptor; Erosive pustular dermatosis of the scalp like eruption; Gefitinib; Scarring alopecia

Indexed keywords

ERLOTINIB; GEFITINIB; LAPATINIB; PREDNISOLONE; STEROID; TEICOPLANIN; VANCOMYCIN;

AGED; ALOPECIA; BACTERIUM CULTURE; BRAIN METASTASIS; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EROSIVE PUSTULAR DERMATOSIS; FEMALE; FOLLICULITIS; GAMMA KNIFE RADIOSURGERY; HAIR DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEUTROPHIL CHEMOTAXIS; PLASMA CELL; PRIORITY JOURNAL; PUNCH BIOPSY; PUSTULE; REVIEW; SKIN APPENDAGE DISEASE; SKIN BIOPSY; SKIN DISEASE;

AGED; ALOPECIA; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SCALP DERMATOSES;

EID: 84867745226     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000341528     Document Type: Review

References (21)

1. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
2. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670. (Pubitemid 44436627)
3. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500. (Pubitemid 40903630)
4. Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, Reimer G, Treudler R, Tsianakas A, Ulrich C, Wollenberg A, Homey B: Management of cutaneous side effects of EGFR inhibitors: Recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 2011; 9: 195-203.
5. Gerber PA, Kukova G, Buhren BA, Homey B: Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222: 144-147.
6. Mak KK, Chan SY: Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem 2003; 278: 26120-26126. (Pubitemid 36835381)
7. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL: Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14: 5216-5223.
8. Yang BH, Bang CY, Byun JW, Han SH, Song HJ, In SG, Shin JH, Choi GS: A case of cicatricial alopecia associated with erlotinib. Ann Dermatol 2011; 23:S350-S353.
9. Hepper DM, Wu P, Anadkat MJ: Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 2011; 64: 996-998.
10. Pye RJ, Peachey RD, Burton JL: Erosive pustular dermatosis of the scalp. Br J Dermatol 1979; 100: 559-566. (Pubitemid 9255466)
11. Burton JL, Peachey RD, Pye RJ: Erosive pustular dermatosis of the scalp - a definition. Br J Dermatol 1988; 119: 411.
12. Wu CY, Chen GS, Lan CC: Erosive pustular dermatosis of the scalp after gefitinib and radiotherapy for brain metastases secondary to lung cancer. Clin Exp Dermatol 2008; 33: 106-107.
13. Yalcin S, Dizdar O, Yalcin B, Gokoz O: Sparing of previously irradiated skin from erlotinib-induced acneiform rash. J Am Acad Dermatol 2008; 58: 178-179. (Pubitemid 350298133)
14. Graves JE, Jones BF, Lind AC, Heffernan MP: Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 2006; 55: 349-353. (Pubitemid 44038007)
15. Costa DB, Kobayashi S, Schumer ST: Erlotinib-associated alopecia in a lung cancer patient. J Thorac Oncol 2007; 2: 1136-1138. (Pubitemid 350307913)
16. Donovan JC, Ghazarian DM, Shaw JC: Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Arch Dermatol 2008; 144: 1524-1525.
17. Ena P, Fadda GM, Ena L, Farris A, Santeufemia DA: Tufted hair folliculitis in a woman treated with lapatinib for breast cancer. Clin Exp Dermatol 2008; 33: 790-791.
18. Pongpudpunth M, Demierre MF, Goldberg LJ: A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Cutan Pathol 2009; 36: 1303-1307.
19. Lin SS, Tsai TH, Yang HH: Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis. Clin Exp Dermatol 2009; 34: 528-530.
20. Hoekzema R, Drillenburg P: Folliculitis decalvans associated with erlotinib. Clin Exp Dermatol 2010; 35: 916-918.
21. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G: Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601. (Pubitemid 35015303)